Delivering Lifesaving Medicines to Patients through Innovation, Regulatory Reform and Global Partnership

Sunday, June 25, 2017

Wayne T. Hockmeyer Auditorium

MedImmune, A Member of the AstraZeneca Group

1 MedImmune Way, Gaithersburg, MD 20878

	Program

7:30 AM – 8:30 AM	Registration and Continental Breakfast; Exhibition Booth Setup
8:30 AM – 8:35 AM	Welcome to the 22nd CBA Annual Conference
Dong Shen, M.D., Ph.D.	, President-elect of CBA
8:35 AM – 8:55 AM	Opening Remarks
8:35 AM – 8:40 AM	John C. Wobensmith, Secretary of State of Maryland
8:40 AM – 8:45 AM	Benjamin H. Wu, Deputy Secretary of the Maryland Department of Commerce
8:45 AM – 8:50 AM AstraZeneca Group	Bahija Jallal, Ph.D., EVP of AstraZeneca, Head of MedImmune, a Member of the
8:50 AM – 8:55 AM	Embassy of the People Republic of China in the USA
8:55 AM – 9:00 AM	Introduction of the CBA Life Achievement Awardees

Xu-Rong Jiang, M.D., Ph.D., President of CBA

9:00 AM – 9:30 AM Lifetime Achievement in Research Award Presentation

Dr. Craig Venter, Co-Founder, Executive Chairman, Head of Scientific Strategy – Human Longevity, Inc., Founder, Chairman, and CEO of the J. Craig Venter Institute, Co-Founder, Executive Chairman, and Co-Chief Scientist of Synthetic Genomics Inc.

9:30 AM – 10:00 AM Lifetime Achievement in Regulatory Science Award Presentations

Dr. Robert Temple, Deputy Director of Clinical Science, FDA CDER

10:00 AM-10:15 AM Coffee Break and Refreshments

10:15 AM—11:15 AM Session 1: Regulatory Innovations at FDA and CFDA: An Opportunity for A Strategic Collaboration

Session Co-chairs: Jingyu (Julia) Luan, Ph.D., FDA, John FinkBohner, Ph.D., AstraZeneca

10:15 AM–10:35 AM Evolution of FDA Pharmaceutical Quality Oversight

Lawrence X. Yu, Ph.D., Deputy Director, Office of Pharmaceutical Quality, FDA/CDER

10:35 AM –10:55 AM Updates on CFDA Drug Regulatory Reform

Xinyu Weng, P.D., Representative of CFDA in US, First Secretory of the Embassy of China in US

10:55 AM-11:15 AM Session 1 Panel Discussion

Panelists:

Dr. Robert Temple, Deputy director of Clinical Science, FDA CDER

Dr. Ning Li, Vice President and Head of Region Asia and China Regulatory and Medical Policy in Sanofi

Dr. Helen Mao, Co-founder and Senior VP of CanSino Biologics Inc.

Dr. Lawrence X. Yu, Deputy Director, Office of Pharmaceutical Quality, FDA/CDER

Dr. Xinyu Weng, Representative of CFDA in US, First Secretory of the Embassy of China in US

11:15 AM-12:30 PM Session 2: Global Collaboration

Session Co-chairs: Ziping Wei, Ph.D., Chief Executive Officer, BridgeBio, LLC, Jenny Zhao, Salubris

11:15 AM-11:30 AM Honorable Mayor Dengxi Wang, Henan Xinxiang delegation

11:30 AM-11:45 AM Mr. Xiang Xian Shao, Shanghai Naili Liuti Equipment Limited Company

11:45 AM–12:00 PM Mrs. Sofia Sun, Marketgene Capital

12:00 PM-12:15 PM Dr. John Li, Salubris

12:15 PM-12:30 PM Dr. Kaifeng Wang, China Recourses Life Science Industry Development Co., Ltd

12:30 PM -1:30 PM Luncheon

Afternoon Sessions

1:30 PM – 2:30 PM Session 3: Precision Medicine

Session Chairs: Chuanhua Julia Xing, Ph.D., Founder, XPrecision

1:30 PM – 1:50 PM Human genome project and the harmony of the society

Dr. Guoping Zhao, Executive director of the Chinese National Human Genome Center at Shanghai (CHGCS) and director of the National Engineering Center for BioChip

1:50 PM – 2:10 PM Sequencing Seattle: Solve Population Health Challenges with Precision Medicine

Dr. Yiwu He, Global Head of R&D at BGI, CEO of BGI Groups USA

2:10 PM - 2:30 PM Precision Medicine Calls For Precision Sequencing

Dr. Stephen Turner, Co-founder and Chief Technology Officer, Pacific Biosciences

2:30 PM – 2:45 PM Break

2:45 PM — 3:45 PM Session 4 Panel discussion: Entrepreneur Adventures of CBA Leaders

Session Chairs: Patrick Lu, Ph.D., Chairman of the Board and CEO, Sirnaomics, Inc.

Panelists:

Dr. Patrick Lu, Chairman of the Board and CEO, Sirnaomics, Inc.

Dr. Weiwu He, Chairman of the Board and CEO, Origene

Dr. Dajun Yang, Chairman of the Board and CEO, Ascentage Pharma

3:45 PM – 4:00 PM Coffee Break and Refreshments

4:00 PM – 5:00 PM Session 5 Panel Discussion: The Relationship between Investor and Entrepreneur

Session Chairs: Lin Sun-Hoffman, Ph.D. JD, Founding Partner at Liu, Zheng, Chen & Hoffman LLP

Panelists:

Dr. Henry Hsu, Founder and CEO, Allysta Pharmaceuticals

Dr. Jimmy Zhang, Chief Executive Officer, Shenzhen CLI Life Science Investment

Dr. Ruhong Jiang, Chief Executive Officer, Applied Stem Cell

Dr. Weiwu He, Chairman of the Board and CEO, Origene

5:00 PM - 6:00 PM Session 6: CBA-SCBA Joint Session - Cell signaling and human diseases

Session Co-chairs: Wang Xinwei, Ph.D., Senior Investigator, Chief, Liver Carcinogenesis Section, Deputy Chief, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Yali Fu, Ph.D., NIH

5:00 PM – 5:15 PM Unconventional protein secretion in health and disease

Dr. Yihong Ye, Senior Investigator, NIH

5:15 PM – 5:30 PM Targeting metabolic deficient pathway for cancer therapy

Dr. Chunzhang Yang, Investigator, NCI

5:30 PM – 5:45 PM Proteomic Instability of Cancer: HSF1 is a Guardian of Cancer Proteostasis

Dr. Chengkai Dai, NIH Stadtman Investigator, Head, Proteomic Instability of Cancer Section, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute

5:45 PM – 6:00 PM Session 6 Panel Discussion

Panelists:

Dr. Yihong Ye, Senior Investigator, NIH

Dr. Chunzhang Yang, Investigator, NCI

Dr. Chengkai Dai, NIH Stadtman Investigator, Head, Proteomic Instability of Cancer Section, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute

6:00 PM – 6:30 PM The Situation and New Policy of Pharmaceutical Industry in China

Dr. Mingde Yu, Honorary Chairman of Chinese Biopharmaceutical Enterprises Association

6:30 PM Closure of Exhibition

6:30 PM Evening Reception